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1. Introduction  
The target of rapamycin (TOR, also called the mechanistic or mammalian target of 
rapamycin, mTOR) is an atypical protein kinase that is highly conserved in eukaryotes 
(Sarbassov et al. 2005; Wullschleger et al. 2006; Jacinto & Lorberg 2008). It modulates cell 
growth, metabolism, and cell survival in response to diverse extracellular and intracellular 
signals, such as growth factors, energy levels, and nutrient status (Reiling & Sabatini 2006; 
Wullschleger et al. 2006; Jacinto 2008). Inhibition of mTOR activity using rapamycin and 
more recently via mTOR active site inhibitors and disruption of mTOR complexes, has 
revealed important insights on how mTOR functions under physiological and pathological 
conditions (Sarbassov et al. 2005; Proud 2011; Zoncu et al. 2011).  
TOR was first identified as the target of rapamycin, a potent antifungal macrolide originally 
purified from Streptomyces hygroscopicus in an Easter Island soil sample in 1975 (Sehgal et al. 
1975; Vezina et al. 1975). This natural compound was later found to possess 
immunosuppressive and growth inhibitory properties on mammalian cells (Hall 1996; Thomas 
& Hall 1997; Young & Nickerson-Nutter 2005). A genetic screen in the budding yeast, 
Saccharomyces cerevisiae, identified three genes that conferred rapamycin resistance upon 
mutation. These genes include TOR1, TOR2, and FPR1 (Heitman et al. 1991). Whereas TOR1 
and TOR2 are relatively large proteins (around 300 kDa) and display homology to lipid 
kinases, FPR1 (also called FKBP12) is a small protein (about 12 kDa) that has cis-trans prolyl 
isomerase activity (Helliwell et al. 1994; Kunz et al. 2000). The activity of TOR/mTOR becomes 
inhibited by the complex formed by rapamycin and FKBP12. TOR orthologues were also 
discovered in mammalian cells (mTOR) and other higher eukaryotes (eg C. elegans TOR, 
CeTOR; Drosophila TOR, dTOR; Arabidopsis thaliana TOR, At TOR) (Brown et al. 1994; Oldham 
et al. 2000; Long et al. 2002; Menand et al. 2002). In this chapter, we will review the conserved 
structures of TOR, the regulation of the mTOR pathway, and summarize its conserved cellular 
functions. We also discuss the value of targeting mTOR function in therapeutic strategies. 
2. Structure, conserved versus divergent sequences in TOR 
TOR/mTOR is encoded by a single gene in most organisms although in some yeasts there 






sequence among different species (Wullschleger et al. 2006). TOR belongs to the 
phosphatidylinositol-3 kinase-related kinase (PIKK) family, a subgroup of atypical protein 
kinases (Hanks & Hunter 1995; Manning et al. 2002; Miranda-Saavedra & Barton 2007). 
PIKKs are conserved from yeasts to mammals and have numerous functions in stress 
responses including DNA repair, transcription, and mRNA decay (Keith & Schreiber 1995). 
The PIKKs share some homology in the catalytic domain with lipid kinases including 
phosphatidylinositol-3 kinases (PI3Ks) (Keith & Schreiber 1995; Manning et al. 2002), but 
they possess serine/threonine kinase activity (Figure 1). The large size of PIKK family 
members (from 280 to 470 kDa) has been a major obstacle in studying the structure of these 
molecules (Knutson 2010). In general, these kinases are roughly defined by an -helical N-
terminal region and a catalytic C-terminal region (Choi et al. 1996; Lempiainen & 
Halazonetis 2009). From the structural prediction of amino acid sequences, PIKK family 
members contain HEAT (Huntington, elongation factor 3, alpha-regulatory subunit of 
protein phosphatase 2A and TOR1) repeats at the amino-terminus, FAT (FRAP-ATM- 
TRRAP) domain, kinase domain (KD), the PIKK-regulatory domain (PRD) and the FAT-C- 
 
Fig. 1. Structural domains of mTOR and conserved amino acid sequences between lipid and 
protein kinases. Numbers indicate the residues in mTOR. FAT, FRAP-ATM-TRRAP domain; 
FRB, FKBP12-rapamycin-binding domain; KD, kinase domain; FIT, found in TOR domain; 
PRD, PIKK-regulatory domain; FATC, FAT-C-terminal domain; HEAT repeat, the protein 
domain found in Huntingtin, Elongation factor 3, protein phosphatase 2A, and TOR1; 
mTOR, mammalian target of rapamycin; ATM, Ataxia telangiectasia mutated; DNA-PK, 
DNA-dependent protein kinase; PI3K, Phosphatidylinositol 3-kinases; Akt, protein kinase B; 
CDK1, Cyclin-dependent kinase 1. 
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terminal (FATC) domain, at the carboxyl-terminus (Bosotti et al. 2000; Jacinto 2008; Hardt et al. 
2011). The configuration of these protein motifs contributes to the catalytic activity and 
function of PIKKs, including TORs (Bosotti et al. 2000; Adami et al. 2007; Yip et al. 2010). 
Understanding the regulation of these motifs is key to unravelling the cellular function of 
TOR/mTOR and will provide insights on how we can manipulate the activity of this protein.  
2.1 HEAT repeats 
The amino-terminus of mTOR is characterized by HEAT repeats. This structural motif 
contains varied numbers of two anti-parallel α-helix repeats that are linked by inter-unit 
loops allowing flexibility in this structure (Perry & Kleckner 2003). A recent sequence 
analysis strategy revealed that there are 30 to 32 tandem HEAT repeats predicted in human, 
fly, plant, and yeast TORs (Knutson 2010). HEAT domains confer a curved-tubular shape, 
facilitating multiple protein-protein interactions in the N-terminal half of mTOR (Groves & 
Barford 1999; Adami et al. 2007). Accordingly, this region is shown to provide a platform for 
protein-protein interaction, where mTOR can bind with protein regulators or substrates. In 
the budding yeast, the TORC components, KOG1 (Kontroller Of Growth 1), AVO1 (Adheres 
VOraciously 1), and AVO3 (Adheres VOraciously 3), associate with TOR at the HEAT region 
of the N-terminus (Wullschleger et al. 2005; Adami et al. 2007; Yip et al. 2010). Similarly, 
raptor, the orthologue of KOG1 in mammalian cells, also interacts with the N-terminal 
region of mTOR and that the intact structure of the HEAT domain in mTOR is essential for 
this interaction (Kim et al. 2002; Adami et al. 2007; Yip et al. 2010).  
2.2 FAT domain and FRB domain 
FAT domain is a hallmark of the PIKK family (Bosotti et al. 2000). In mTOR and other PIKK 
members, the FAT domain is adjacent to the N-terminal portion of the catalytic region 
(Lempiainen & Halazonetis 2009; Hardt et al. 2011). Although the overall structure of FAT 
domains in mTOR is still unclear, it is suggested that this domain is composed entirely of -
helices according to sequence analysis and can be viewed as an extension of HEAT repeats. 
This would suggest that it serves as a platform for protein interaction as well (Perry & 
Kleckner 2003; Adami et al. 2007). Furthermore, the FAT domain may associate with another 
domain (FATC) to wedge the KD into a proper configuration and ensure the catalytic 
activity of mTOR (Bosotti et al. 2000).  
The C-terminus of the FAT domain is where rapamycin, in complex with FKBP12, binds 
mTOR (Stan et al. 1994; Chen et al. 1995). This small structural motif, consisting of around 100 
amino acids, has been termed as the FKBP12-rapamycin-binding (FRB) (Veverka et al. 2008). 
Structural and biochemical analyses have revealed that this motif can also bind to 
phosphatidic acid (PA), a lipid secondary messenger (Fang et al. 2001; Veverka et al. 2008). 
Upon mitogen stimulation, the level of PA is enhanced due to the activation of phospholipase 
D (English 1996). Although it is unclear whether PA can activate mTOR directly, it is 
suggested that PA may direct the membrane localization of mTOR (Veverka et al. 2008).  
2.3 FATC domain 
FATC, a protein motif containing around 30 amino acids, is conserved with high sequence 






these kinases, the FATC domain is at the end of the C-terminal tail and exists in combination 
with the FAT domain to flank the kinase domain (Bosotti et al. 2000; Jacinto & Lorberg 2008) 
(Figure 1). Low-resolution structure of this domain in yeast TOR1, visualized by electron 
microscopy, suggests that this motif protrudes from the catalytic core domain (Adami et al. 
2007; Lempiainen & Halazonetis 2009). However, it is also predicted that the attachment of 
FATC to the KD is required for the proper conformation and activation of the latter. 
Structural studies utilizing NMR spectroscopy uncover that the FATC domain contains an 
-helix followed by a sharp turn, which is stabilized by a disulfide bond between two 
cysteine residues (Dames et al. 2005). The substitution of cysteine with serine increases the 
flexibility of FATC and leads to a lower expression level of TOR2 in budding yeast (Dames 
et al. 2005). Moreover, other mutagenesis assays have implied that the substitution and 
deletion of the hydrophobic residues in this domain abolish the autophosphorylation of 
mTOR and the mTOR-dependent phosphorylation of eukaryotic initiation factor 4E-binding 
protein (4E-BP) and p70 S6 kinase (S6K) (Peterson et al. 2000). Together, these studies 
indicate that the FATC domain modulates both kinase activity and stability of TOR. 
2.4 PRD (FIT) 
The PRD domain is a newly identified motif situated between the kinase and FATC 
domains in PIKK family members (Mordes et al. 2008). Unlike other C-terminal domains, 
this domain is not conserved in all PIKKs and its length varies between 16 to 82 amino acids 
(Mordes et al. 2008). In TOR, this region is also named the Found in TOR (FIT) domain 
(Sturgill & Hall 2009; Hardt et al. 2011). Its N-terminal half, which shows almost no 
sequence homology with other PIKKs, is defined as a suppressor of TOR activity. The 
deletion of residues 2430 to 2450 of rat mTOR enhances kinase activity of both mTOR and its 
downstream targets, in vitro and in vivo respectively (Brunn et al. 1997; Sekulic et al. 2000). 
The mitogen- and nutrient-induced post-translational phosphorylation on several residues 
in the FIT domain, eg Thr 2446, Ser 2448, and Ser 2481 is used as a marker of mTOR 
activation (Chiang & Abraham 2005; Holz & Blenis 2005; Copp et al. 2009). Thus, the 
phosphorylation in this region could relieve the suppressive action conferred by this 
domain. 
2.5 Catalytic domain and kinase activity of mTOR 
In the classification of eukaryotic protein kinases, mTOR belongs to the atypical group, a 
subset of protein kinases lacking sequence similarity to conventional protein kinases (Hanks 
& Hunter 1995) . In fact, the catalytic sequence of mTOR shares high homology with PI3K 
family, a lipid kinase family, but mTOR has been experimentally demonstrated to possess 
Serine/Threonine protein kinase activity (Alarcon et al. 1999). The segment from residues 
Lys2187 to Phe2421 comprises the catalytic region of mTOR (Hardt et al. 2011). Within this 
domain, two conserved structures are proposed to contribute to the kinase activity of 
mTOR: the catalytic loop, which contains the predicted catalytic base (Asp2338) in the triplet 
DRH residues (Hardt et al. 2011), and the activation loop (also called T loop), consisting of 
twenty to thirty amino acids that connects the N- and C-lobes of the kinase domain 
(Lochhead 2009). By general definition, activation loop begins with the DFG sequence and 
ends with the PE sequence (Figure 1). In conventional protein kinases, there is one 
phosphorylatable Ser, Thr, or Tyr residue existing within the region and the 
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phosphorylation at this residue is required for kinase activation. In most cases, either the 
kinase itself (autophosphorylation) or an upstream kinase mediates the phosphorylation of 
this site. However, in atypical protein kinases, such as mTOR, this phosphorylatable residue 
is substituted by an Asp or Glu, which mimics the phosphorylated state of the T loop. 
Hence, instead of the conventional phosphorylation-activation mechanism in the T loop, 
other cis- and trans-acting mechanisms modulate mTOR activity. As discussed above, the 
phosphorylation at the PRD could promote mTOR activity. mTOR could also be potentially 
regulated via FATC domain stability. The formation of disulfide bonds may stabilize the 
FATC structure, or even the whole mTOR protein (Sarbassov & Sabatini 2005). Due to this 
unique structural feature, it has been proposed that the FATC domain could act as a redox-
sensor to regulate mTOR activity (Dames et al. 2005). In this model, the presence of nutrients 
could enhance mitochondria metabolism that alters the intracellular redox environment. 
Although it remains to be examined, this redox change could be sensed by the FATC 
domain and confer a conformation switch in mTOR thereby altering its activity in response 
to intracellular stimuli (Dames et al. 2005). Other regulatory mechanisms such as association 
with regulatory partners and subcellular localization are discussed in Section 4. 
3. mTOR protein complexes 
Forming protein complexes is a common and efficient way to acquire different functional 
modules in a spatial and temporal manner (Hartwell et al. 1999; Pereira-Leal et al. 2006). As 
described in the previous section, the multiple motif conformation and superhelical structure 
of mTOR enables this protein to associate with diverse cofactors. Early studies using gel 
filtration chromatography suggested that TOR could be part of multi-protein complexes (Yang 
& Guan 2007). This was supported by findings that TOR has a rapamycin-insensitive function 
in yeast, implying that two complexes could perform distinct functions (Zheng, 1995; Schmidt, 
1996; Zheng, 1997). Indeed, in a number of organisms with perhaps the exception of plants and 
algae, there are two structurally and functionally distinct TOR complexes (Loewith et al. 2002; 
Wedaman et al. 2003; Matsuo et al. 2007; Diaz-Troya et al. 2008). In this section, both conserved 
and non-conserved components of TOR complexes will be discussed. 
3.1 mTORC1 
3.1.1 Raptor (KOG1) 
KOG1 was first identified to co-purify with TOR1 in budding yeast (Loewith et al. 2002). In 
mammals, the KOG1 orthologue, raptor, was found to associate with mTOR (Hara et al. 
2002; Kim et al. 2002). It is predicted that the C-terminal half of KOG1 and raptor consists of 
four HEAT repeats and seven WD40 repeats (Loewith et al. 2002; Wedaman et al. 2003; 
Adami et al. 2007; Yip et al. 2010). Due to their motif configuration, it is speculated that 
KOG1 and raptor function as scaffold proteins to facilitate the association between TORC1 
(mTORC1) and downstream substrates (Loewith et al. 2002; Adami et al. 2007). Deletion of 
kog1 in budding yeast and knockout of raptor in mice both led to lethality, implying that 
these genes are essential for normal development and cellular functions (Loewith et al. 2002; 
Murakami et al. 2004; Guertin et al. 2006). 
In mammalian cells, raptor binds to mTOR in a rapamycin-sensitive or nutrient-responsive 






towards its substrates such as S6K and 4E-BP1 in response to insulin and nutrients (Kim et 
al. 2002). Presence of rapamycin/FKBP12 complex diminishes the association between 
raptor and mTOR, which could explain how rapamycin can inhibit mTORC1 function (Kim 
et al. 2002; Kim et al. 2003; Oshiro et al. 2004).  
3.1.2 mLST8 (LST8) 
LST8 is a 34 kDa protein composed of seven WD40 repeats (Chen & Kaiser 2003). Originally, 
LST8 was identified because of its function in the translocation of amino acid permease 
GAP1 from Golgi to cell surface (Roberg et al. 1997; Liu et al. 2001). Later, LST8 (Wat1 in 
fission yeast) was found in both TORC1 and TORC2 complexes (Chen & Kaiser 2003; 
Alvarez & Moreno 2006; Matsuo et al. 2007). Specifically, LST8 binds to the catalytic domain 
in the C-terminal region of TOR2 and regulates its kinase activity. In addition, it has been 
shown that LST8 is required for TORC2 complex integrity (Wullschleger et al. 2005). 
Similarly, mammalian LST8 (mLST8, also known as GL) was first reported to interact with 
raptor and mTOR in a nutrient- and rapamycin- sensitive manner (Kim et al. 2003). mLST8 
is only required for mTORC2 functions in the early development of mice (Guertin et al. 
2006). Knockout of mLST8 in mice revealed that it is required for mTORC2 function but not 
for the mTORC1 function in S6K phosphorylation (Guertin et al. 2006).  
3.2 mTORC2 
3.2.1 Rictor (AVO3) 
AVO3, a 164-kDa protein, is a conserved subunit of TORC2 in budding yeast (Loewith et al. 
2002). It was first identified as a suppressor of sphingolipid biosynthesis mutants in a 
genetic screen (Dunn et al. 1998). The presence of AVO3 is required for the integrity of 
rapamycin-insensitive TOR complex but it is dispensable for the in vitro kinase activity of 
TOR2 (Wullschleger et al. 2005). Therefore, AVO3 is suggested to play a role in recruiting 
TORC2 substrates (Ho et al. 2008).  
Rictor (rapamycin-insensitive companion of mTOR) is the mammalian orthologue of yeast 
AVO3 and is part of mTORC2 (Jacinto et al. 2004; Sarbassov et al. 2004). It lacks common or 
known structural motifs but its C-terminus is conserved among vertebrates. Knockdown or 
ablation of rictor in mammalian cells led to defective phosphorylation of several members of 
the AGC (protein kinase A, G, and C) kinase family, including Akt, SGK1 and PKC, 
decreased cell survival upon stress induction, and impaired reorganization of actin 
cytoskeleton (Jacinto et al. 2004; Sarbassov et al. 2004; Guertin et al. 2006; Shiota et al. 2006; 
Garcia-Martinez & Alessi 2008). In mouse models, rictor knockout is embryonic lethal and 
the rictor-/- MEFs (mouse embryonic fibroblasts) isolated from rictor null embryos display 
slower growth rate compared to wild type MEFs (Guertin et al. 2006; Shiota et al. 2006). 
Substitution of Gly934 in rictor prevented formation of rictor/SIN1 heterodimer and reduced 
mTORC2 activity (Aimbetov et al. 2011). Thus, the interaction between rictor and SIN1 is 
required to form an integral and active mTORC2. 
3.2.2 SIN1 (AVO1) 
AVO1 is another TORC2 component in budding yeast and binds to the N-terminus of TOR2. 
The depletion of AVO1 mimics the defective actin polarization phenotype observed in the 
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tor2 mutant strain (Loewith et al. 2002). Sin1, the orthologue of AVO1 in fission yeast, was 
first identified as a stress-responsive protein that interacts with Sty1/Spc1 mitogen-
activated protein (MAP) kinase, a member of yeast stress-activated MAP kinase (SAPK) 
family (Wilkinson et al. 1999; Yang et al. 2006). Mammalian SIN1 is also implicated in the 
JNK (c-Jun N-terminal kinase) and MAPK (mitogen-activated protein kinase)/ERK 
(extracellular-regulated-protein kinase) pathways (Cheng et al. 2005; Schroder et al. 2005). It 
was later identified as a critical subunit of mTORC2 (Frias et al. 2006; Jacinto et al. 2006; 
Yang et al. 2006). To date, more than five alternatively spliced isoforms of mammalian SIN1 
have been discovered (Schroder et al. 2004; Cheng et al. 2005). Three of these isoforms form 
distinct rapamycin-insensitive mTOR complexes with rictor and mTOR (Frias et al. 2006). 
SIN1 disruption affects both mTORC2 assembly and function. Loss of SIN1 is embryonic 
lethal, indicating an important role for this protein in development (Jacinto et al. 2006; Yang 
et al. 2006). 
3.3 Other interactors 
In addition to the main components of TOR complexes discussed above, there are many 
non-conserved proteins that associate with TOR/mTOR. Some of these mTORC interactors 
can affect mTOR activity. These mTORC-interacting molecules could also mediate crosstalk 
between the mTOR pathway and other signaling pathways (Woo et al. 2007).  
In budding yeast, TCO89 (TOR complex one 89 kDa subunit) has been shown to associate 
with TORC1 (Reinke et al. 2004). Deletion of TOR1 and TCO89 results in rapamycin 
hypersensitivity and defective cell-wall integrity, respectively. AVO2 and BIT61 also 
associate with TORC2 but their roles in regulating TORC2 functions remain to be elucidated 
(Loewith et al. 2002; Reinke et al. 2004). BIT61 can associate with SLM1 and SLM2, which are 
also TORC2-associated proteins mediating actin cytoskeleton organization (Fadri et al. 
2005).  
PRAS40 (proline-rich Akt substrate of 40kDa) is a negative regulator of mTORC1 (Sancak et 
al. 2007; Wang et al. 2007). PRAS40 and mTORC1 substrates, such as 4E-BP-1 and S6K, share 
a similar raptor-binding motif, the TOR signaling (TOS) motif (Wang et al. 2007). Therefore, 
it is speculated that PRAS40 can directly bind to raptor and interfere with the ability of 
mTORC1 to interact with its substrates (Wang et al. 2007). This negative regulation of 
mTORC1 by PRAS40 is inhibited by the insulin signaling pathway, since activated Akt can 
phosphorylate PRAS40 and prevent its binding to raptor (Sancak et al. 2007).  
PRR5 (proline-rich protein 5), also named Protor (protein observed with rictor), and PRR5L 
(PRR5-like) bind to rictor and non-essential subunits of mTORC2 (Pearce et al. 2007; 
Thedieck et al. 2007; Woo et al. 2007). Knockdown of these two proteins did not cause 
significant disruption of both complex integrity and kinase activity of mTORC2. Protor1 is 
required for the phosphorylation of SGK1, but not of Akt and PKC, specifically in mouse 
kidney (Pearce et al. 2011). These findings suggest that this non-conserved interactor might 
regulate mTORC2 function in a tissue- and target- specific manner (Pearce et al. 2011). 
DEPTOR (DEPDC6, DEP domain-containing protein 6), is a negative regulator of mTOR 
that associates with both mTORC1 and mTORC2 (Peterson et al. 2009; Proud 2009). Loss of 
DEPTOR activates S6K1 and Akt, downstream substrates of mTORC1 and mTORC2, 






multiple myelomas harboring cyclin D1/D3 or c-MAF/MAFB translocations. The high 
DEPTOR levels in these cells are required for the activation of PI3K/Akt pathway and may 
suppress apoptosis (Peterson et al. 2009). Several studies have characterized how DEPTOR 
levels can be controlled (Duan et al. 2011; Gao et al. 2011; Zhao et al. 2011). DEPTOR is 
recognized and ubiquitinated by an F box protein, SCF (TrCP) and degraded through the 
26S-proteasome pathway (Zhao et al. 2011). Either expressing the dominant-negative 
mutant of TrCP or interfering with the interaction between DEPTOR and TrCP via 
mutagenesis causes the accumulation of DEPTOR and downregulation of mTOR activity 
(Zhao et al. 2011). Furthermore, mTORC1 and mTORC2 could directly phosphorylate 
DEPTOR (Gao et al. 2011). CK1 (casein kinase 1) can generate a phosphodegron on the 
phosphorylated DEPTOR, which is bound by TrCP to induce the degradation of DEPTOR 
(Duan et al. 2011; Gao et al. 2011). The degron mutant and TrCP deletion can inhibit 
DEPTOR degradation and decrease mTOR activities (Gao et al. 2011). Together, these 
studies suggest that DEPTOR can regulate mTORC activity via a positive feedback loop 
involving mTOR itself and CK1. 
4. Mode of regulation of mTOR complexes 
mTOR serves to relay signals from growth cues to downstream events to consequently 
control cell growth and metabolism (Wullschleger et al. 2006; Zhou & Huang 2010). Below, 
we discuss how these growth cues alter mTOR activity via regulation of mTOR complex 
component modification, subcellular localization, and association with other regulatory 
molecules.  
4.1 Phosphorylation 
mTOR itself is regulated via phosphorylation. Ser1261 phosphorylation of mTOR is induced 
by insulin stimulation and is required for mTORC1 activity and mTOR autophosphorylation 
(Acosta-Jaquez et al. 2009). Furthermore, mTOR in the context of intact mTORC1 is 
predominantly phosphorylated at the Ser2448 residue (Copp et al. 2009). This site is 
phosphorylated by S6K in a mitogen- and nutrient-inducible manner (Chiang & Abraham 
2005). The autophosphorylation site at Ser2481 is also growth-signal dependent (Peterson et 
al. 2000). A later report proposed that the Ser2481 phosphorylation event is an indicator of 
functional mTORC2 (Copp et al. 2009). Prolonged but not acute rapamycin treatment, which 
disrupts mTORC2 (Sarbassov et al. 2006), can abolish mTOR phosphorylation at this site 
(Copp et al. 2009). However, mTOR from raptor immunoprecipitates is also phosphorylated 
at Ser2481. Furthermore, inhibition of mTORC1 by acute rapamycin treatment can reduce 
Ser2481 phosphorylation of mTOR that is associated with raptor (Soliman et al. 2010), 
implying that the phosphorylation of Ser2481 residue may also be involved in the regulation 
of mTORC1 functions. Thus, how Ser2481 phosphorylation affects the specific activity of 
mTORC1 vs mTORC2 would need to be clarified.  
mTOR complex components are also phosphorylated at numerous sites. Phosphorylation of 
raptor at different residues may affect the kinase activity of mTOR. For example, AMPK 
mediates phosphorylation of raptor at Ser722/792 upon nutrient depletion and inhibits 
mTORC1 function (Gwinn et al. 2008). In contrast, upon mitogen stimulation, p90 ribosomal 
S6 kinase (RSK) and mTORC1 mediate raptor phosphorylation at Ser719/721/722 and Ser863, 
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respectively, which is essential for mTORC1 activation (Carriere et al. 2008). Rictor is 
predicted to be phosphorylated in at least 37 phosphorylation sites according to MS/MS 
analysis and phospho-proteome database (Dibble et al. 2009; Julien et al. 2010). These 
putative phosphorylation sites mainly localize in the C-terminal region of rictor, which is 
conserved only in vertebrates (Dibble et al. 2009; Julien et al. 2010). Thus, rictor could have 
acquired more diverse functions and complex regulation during evolution . Several studies 
have examined the function of rictor phosphorylation at Thr1135 residue located in the C-
terminal region. This phosphorylation is mediated by S6K1 in an amino acid- and growth 
factor- dependent manner and is suggested to act as a feedback regulation of mTORC2 from 
mTORC1 signals (Dibble et al. 2009; Julien et al. 2010; Treins et al. 2010). Its effect on the 
mTORC2-mediated Akt activation is very minimal if any (Boulbes et al. 2010; Treins et al. 
2010). Moreover, in SIN1-/- MEFs, in which mTORC2 complex integrity is disrupted, this 
phosphorylation is still detectable, suggesting that it might be involved in mTORC2-
independent functions (Boulbes et al. 2010). Rictor is also phosphorylated at Ser1235 by 
GSK3 under ER stress conditions (McDonald et al. 2008). This phosphorylation event 
reduces the binding between mTORC2 and its substrate, Akt, hence negatively regulating 
mTORC2.  
SIN1 can also be phosphorylated at multiple sites although the relevant sites remain to be 
identified. Hypophosphorylation of SIN1 interferes with its association with mTOR (Yang et 
al. 2006), but not with rictor (Rosner & Hengstschlager 2008). mTOR can phosphorylate 
SIN1 in vitro, which may prevent SIN1 degradation from lysosomal pathway in vivo (Chen & 
Sarbassov 2011). Other kinases that can phosphorylate SIN1 to regulate mTORC2 activity 
would need to be investigated. 
4.2 Component stability and complex formation 
The activity and specificity of mTOR can be modulated through complex assembly. 
Disruption of mTOR complexes via gene ablation or knockdown of a specific mTORC 
component has revealed the importance of an intact mTORC for phosphorylation of its 
downstream substrates. For instance, in the adipose-specific raptor knockout mice, which 
carry disrupted mTORC1, S6K phosphorylation in white adipose tissue was diminished 
(Boulbes et al. 2010). Similarly, the deletion of either SIN1 or rictor in MEFs and HeLa cells 
inhibited mTORC2 assembly and abolished Akt HM and TM phosphorylation (Guertin et al. 
2006; Jacinto et al. 2006; Yang et al. 2006). 
In mammalian cells, raptor binds to mTOR in a nutrient- responsive manner (Kim et al. 
2002; Oshiro et al. 2004). Upon nutrient deprivation, raptor and mTOR form a stable 
interaction, which can inhibit mTORC1 activity (Kim et al. 2002). Under growth favorable 
conditions, the association between raptor and mTOR is less tight and presumably can 
promote mTORC1 activity towards its substrates such as S6K and 4E-BP (Kim et al. 2002). 
Instead of affecting the intrinsic kinase activity of mTOR, rapamycin/FKBP12 complex is 
proposed to attenuate the association between mTOR and raptor, thereby inhibiting 
mTORC1 (Chen et al. 1995; Choi et al. 1996; Kim et al. 2002). Supporting this model, mTOR 
purified from rapamycin-treated cells showed no defect of its autophosphorylation ability in 
vivo or kinase activity toward substrates in vitro (Peterson et al. 2000). In addition, recent 
studies revealed that not all mTORC1 functions can be inhibited by rapamycin, suggesting 






While the FKBP12/rapamycin complex binds and inhibits mTORC1, it does not affect 
mTORC2 activity acutely perhaps because it does not bind to mTORC2 (Jacinto et al. 2004). 
However, chronic exposure to rapamycin could disrupt mTORC2 function in some cell lines 
presumably by blocking assembly of newly synthesized mTORC2 subunits (Sarbassov et al. 
2006).  
The integrity of mTORC2 is dependent on stability of the rictor/SIN1 heterodimer. These 
mTORC2 components interact tightly and deficiency in either one leads to destabilization of 
the other, suggesting they require each other for stability (Guertin et al. 2006; Jacinto et al. 
2006; Yang et al. 2006). Other proteins associating with mTORC components have been 
identified that could affect mTORC activity or assembly. The folding chaperone Hsp70 
interacts with rictor and its knockdown reduces rictor level as well as mTOR-rictor 
interaction, resulting in impaired mTORC2 formation and activity (Martin et al. 2008; Martin 
et al. 2008). The maturation and assembly of mTORCs was also shown to be dependent on 
Tel2 and Tti (Takai et al. 2007; Kaizuka et al. 2010 a; Kaizuka et al. 2010 b). Hsp90 was 
shown to mediate the formation of both TORCs, as well as other PIKKs (Horejsi et al. 2010; 
Takai et al. 2010). Whether mTORC signaling can be modulated by these interactors remains 
to be examined.  
mTORC2 components have been found to associate with other proteins independently of 
mTOR. Rictor can form an E3 ligase complex with Cullin-1 and Rbx1 to promote the 
ubiquitination of SGK1 in an mTOR-independent manner (Gao et al. 2010). The interaction 
between rictor, Cullin-1, and Rbx1 is disrupted when rictor is phosphorylated at Thr1135 
residue by multiple AGC kinases (Gao et al. 2010). Whether the phosphorylated rictor 
released from the E3 ligase complexes can affect mTORC2 assembly remains to be 
elucidated. SIN1 also interacts with other proteins independently of mTOR and rictor. The 
function of SIN1 when associated with these proteins remains unclear but these proteins are 
involved in stress responses including ras, MEKK2, JNK, p38, ATF2 and the stress-related 
cytokine receptors IFNAR2, TNFR1/2 (Schroder et al. 2005; Makino et al. 2006; Schroder et 
al. 2007; Ghosh et al. 2008).  Unlike mTORC2 components, so far, the mTORC1 subunit 
raptor has not been found to associate with other proteins in an mTORC1-independent 
manner. 
4.3 Localization of mTOR complexes 
Compartmental localization enables a protein kinase to gain access to its regulators or 
effectors, thereby regulating its function. Supporting this concept, yeast TOR undergoes 
nuclear localization and binds to the 35S rDNA promoter to enhance 35S rRNA synthesis in 
a nutrient-sensitive fashion (Li et al. 2006). The HTH (helix-turn-helix) motif, a region in the 
HEAT domain of TOR, has been demonstrated to be essential for this association since HTH 
deletion interrupts the binding of TOR1 to 35S rDNA (Li et al. 2006). TOR1 and TOR2 also 
localize to membrane compartments that contain actin cytoskeleton and endocytosis 
regulators via their HEAT domain (Kunz et al. 2000; Aronova et al. 2007). Two endoplasmic 
reticulum (ER) and Golgi localization sequences were characterized in the HEAT domain, 
supporting that the TOR complexes may localize at the membrane periphery of these 
organelles (Liu & Zheng 2007). The best example for how mTORC1 can be regulated via 
localization is the recent finding that amino acid stimulation induces shuttling of mTORC1 
to late endosomes and lysosomes (LELs) by interaction with Rag GTPases (Sancak et al. 
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2008). How the presence of amino acids would be sensed by mTORC1 interactors in a 
particular organelle such as the endosomes remain to be further elucidated. 
Less is known on how mTORC2 can be compartmentalized and activated in response to 
growth signals. It co-localizes predominantly in the ER periphery (Boulbes et al. 2011). 
mTORC2 associates with actively translating ribosomes and specifically interacts with the 
proteins from the 80S large ribosomal subunit (Oh et al. 2010; Zinzalla et al. 2011). mTORC2 
components can stably interact with ribosomal proteins that line the tunnel exit of the 80S 
and could function in this site by modifying emerging nascent polypeptides such as Akt (Oh 
et al. 2010). mTORC2 becomes activated upon association with ribosomes although the 
precise mechanism is currently unclear (Zinzalla et al. 2011). Since the protein synthesis 
machinery can physically associate with cell surface receptors (Tcherkezian et al. 2010), it 
can be speculated that mTORC2 could be activated upon nucleation of translation 
machinery with a signaling receptor in the membrane periphery. 
5. Upstream regulators of mTOR complexes 
5.1 Activation of mTORC1 
mTORC1 integrates signals from extracellular and intracellular sources of nutrients with 
other growth, energy and mitogenic cues (Figure 2). mTORC1 activity is sensitive to 
intracellular amino acid concentration, particularly leucine depletion (Hay & Sonenberg 
2004). Previously, intracellular amino acid levels were proposed to modulate mTORC1 
activity via TSC1/2 (tuberous sclerosis complex 1/2) (Gao et al. 2002). However, in TSC2-/- 
cells, attenuated mTORC1 activity upon amino acid withdrawal was still detected (Smith et 
al. 2005), indicating the presence of additional pathways regulating mTORC1 activity in 
response to amino acid levels. Furthermore, hVPS34, a class III PI3K, can signal amino acid 
availability to mTORC1 bypassing the TSC1/2-Rheb axis (Byfield et al. 2005; Nobukuni et al. 
2005). Recently, in both yeast and mammals, TORC1/mTORC1 activity has been shown to 
be regulated by Rag GTPases in response to amino acids. In yeast, Rag orthologues Gtr1 and 
Gtr2, as part of the EGO complex (consisting of EGO1, EGO3, Gtr1 and Gtr2) localize to the 
vacuolar/lysosomal membrane and could mediate amino acid signals to TORC1 (Dubouloz 
et al. 2005; Binda et al. 2009). Mammalian Rags function as heterodimers, wherein Rag A/B 
associates with Rag C/D (Sekiguchi et al. 2001). A protein complex termed the Ragulator 
consisting of MAPK scaffold protein 1, p14, p18 localizes Rag to these membrane 
compartments. In nutrient replete conditions, Rag complexes are fully activated as Rag A/B 
in GTP form and Rag C/D in GDP form (Sekiguchi et al. 2001). Activation of Rag 
heterodimers recruits mTORC1 to the membrane compartment where Rheb (Ras homolog 
enriched in the brain) is enriched, thus promoting mTORC1 activity (Rubio-Texeira & Kaiser 
2006; Meijer & Codogno 2008; Sancak et al. 2008). p62, an adaptor protein that associates 
with mTORC1 and Rag complex was shown to be required for mTORC1 activation (Duran 
et al. 2011). It was proposed that p62 can promote the localization of mTORC1 and Rag 
complex to the lysosomes, which is a critical step of mTORC1 activation, in an amino-acid 
dependent manner (Duran et al. 2011). Rheb is a small GTPase belonging to the Ras family 
(Garami et al. 2003; Manning & Cantley 2003; Long et al. 2005). Upon binding to mTOR, 
GTP-loaded Rheb induces a conformational change in the KD of mTOR to promote its 
activation (Long et al. 2005). In the lysosomes, the amino acid transporter PAT1 (proton-






lysosomal amino acid transporter (Russnak et al. 2001). This transporter could play a role in 
mTORC1 activation in an amino acid-dependent manner (Heublein et al. 2010). Knockdown 
of PAT1 in MCF-7 cells led to decreased S6K and 4E-BP-1 phosphorylation (Heublein et al. 
2010). Two membrane transporters, SLC7A5 and SLC3A2, were also shown to be required for 
mTORC1 activation (Nicklin et al. 2009). These two transporters function in the cellular uptake 
and the subsequent efflux of glutamine in the presence of essential amino acids (Nicklin et al. 
2009). This process can increase intracellular concentration of leucine and can enhance 
mTORC1 activation via Rag complexes (Sancak et al. 2008). Thus, several regulatory molecules 
in the endosome/lysosomes and membrane compartments could regulate mTORC1 function 
in response to the presence of amino acids. 
Numerous cellular inputs that convey growth or stress conditions are coupled to mTORC1 
via the TSC1/2 tumor suppressor complex (Castro et al. 2003; Garami et al. 2003; Tee et al. 
2003; Hay & Sonenberg 2004; Zoncu et al. 2011). Loss of TSC1 or TSC2 genes, encoding 
hamartin and tuberin respectively, is observed in tuberous sclerosis, a human genetic 
disorder characterized by benign tumors (Green et al. 1994; Onda et al. 1999). Through 
phosphorylation at different residues, the activity of the TSC 1/2 complex can be regulated 
by different upstream signaling pathways (Huang & Houghton 2003). In the presence of 
growth factors, such as insulin, the insulin receptor is activated and recruits the insulin 
receptor substrate (IRS). IRS serves to couple signals to downstream molecules including 
PI3K, which converts phosphatidylinositol-4,5-phosphate (PIP2) into phosphatidylinositol-
3,4,5-phosphate (PIP3) in the plasma membrane. PIP3 can recruit both PDK1 and Akt to the 
membrane, where Akt is phosphorylated and activated by PDK1. The activated Akt can 
directly phosphorylate TSC2 and block the activity of TSC1/2 complex (Huang & Houghton 
2003), which consequently results in the activation of mTORC1 and the phosphorylation of 
S6K and 4E-BP1, the two best-characterized effectors of mTORC1 (Valentinis & Baserga 2001). 
The regulation of mTORC1 activity via Akt can be counteracted by GADD34 (growth arrest 
and DNA damage protein 34) (Minami et al. 2007; Watanabe et al. 2007). By interacting with 
TSC1/2 complexes, GADD34 inhibits phosphorylation of TSC2 at the Akt phosphorylation 
site Thr1462, thus negatively regulating mTORC1 (Minami et al. 2007; Watanabe et al. 2007).  
The mitogen activated protein kinase (MAPK) pathway can also modulate mTORC1 
functions via negative regulation of TSC1/2 in response to growth cues (Ma et al. 2005). In 
the presence of growth factors, receptor tyrosine kinases activate Ras-Erk1/2 signaling 
(Pearson et al. 2001). Activated Erk can phosphorylate TSC2 at Ser664 and induce dissociation 
of TSC1/2 complex, which suppresses TSC1/2 functions toward cell proliferation and 
transformation (Ma et al. 2005). Active Ras can also inactivate TSC via Rsk-mediated 
phosphorylation of TSC2 at Ser1798, resulting in increased mTORC1 signaling (Roux et al. 
2004). 
AMP-activated protein kinase (AMPK) pathway is another well-established regulatory 
input of mTORC1 in response to energy conditions. Under low cellular energy level (high 
AMP/ATP ratio), LKB1, a tumor suppressor, activates AMPK to directly phosphorylate 
TSC2 at Thr1227 and Ser1345 residues (Inoki et al. 2003; Corradetti et al. 2004; Shaw et al. 2004). 
Unlike Akt and Erk, AMPK-mediated phosphorylation enhances the GAP activity of 
TSC1/2 complex and inhibits mTORC1 function. This would provide a mechanism for 
downregulating energy-consuming cellular processes under low ATP levels.  
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5.2 Activation of mTORC2 
Early studies in yeast have elucidated how TORC2 can control actin cytoskeleton 
polarization but the signals that control TORC2 activity has been elusive (Schmidt et al. 
1996; Schmidt et al. 1997; Loewith et al. 2002). Since this function of TORC2 is viewed to 
control growth spatially, it is reasonable to speculate that TORC2 is activated by growth 
signals. In mammals, mTORC2 activity is promoted by growth factors in a PI3K-dependent 
manner. After insulin stimulation, the phosphorylation of Akt at its hydrophobic motif 
(HM; Ser473) mediated by mTORC2 is significantly increased in vivo (Hresko & Mueckler 
2005; Sarbassov et al. 2005). Similar results were also observed in in vitro kinase assays 
(Sarbassov et al. 2005). Since mTORC2 also phosphorylates sites in Akt and PKC in a 
constitutive manner (Facchinetti et al. 2008; Ikenoue et al. 2008), its responsiveness to 
growth factors has been puzzling. However, further studies revealed that mTORC2 could 
phosphorylate the constitutive site in Akt during translation (Oh et al. 2010). This would 
suggest that conditions that enhance translation, such as the presence of growth factors, 
promote mTORC2 activity. Supporting this notion, mTORC2 was found to associate with 
translating ribosomes and this association is enhanced in cells with increased PI3K signaling 
(Oh et al. 2010; Zinzalla et al. 2011). Since nutrients are essential for promoting protein 
synthesis, this would suggest that mTORC2 would also be regulated by nutrients. However, 
it remains to be determined if this is the case and how mTORC2 becomes activated upon 
association with ribosomes.  
6. mTOR functions 
A number of diverse functions have been ascribed to mTOR but it is now emerging that it is 
a central hub to regulate growth and metabolism (Figure 2). In the whole organism, mTOR 
is required during early development. Rapamycin treatment inhibited amino acid 
stimulation of embryo outgrowth in mice at blastocyst stage (Martin & Sutherland 2001). 
Similarly, the embryonic development of mTOR-/- mice is aberrant and arrested at E5.5 
(Gangloff et al. 2004). Conditional knockout strategies have shed light on tissue-specific 
mTOR functions. The inactivation of mTOR in T cells caused defects in differentiation of 
peripheral T lymphocytes (Delgoffe et al. 2009). The muscle-specific mTOR knockout mice 
displayed reduced levels of dystrophin and severe myopathy, which led to premature death 
(Risson et al. 2009). While there was no significant phenotype in mice with specific deletion 
of mTOR in the prostate, tumor initiation and progression in PTEN-/- mice, which possess 
hyperactivated mTORC1, was suppressed (Nardella et al. 2009). These findings support a 
critical role for mTOR itself in organism and organ development as well as disease 
progression.  
The cellular functions of mTOR have surfaced from numerous studies over the years. The 
most well characterized function of mTOR is the rapamycin-sensitive control of protein 
synthesis by mTORC1. More recent studies have revealed that mTOR has rapamycin-
insensitive functions both as part of mTORC1 and mTORC2. Most of the mTOR functions 
that have been elucidated are mediated by the AGC kinases S6K, Akt, SGK, and PKC. 
Another well characterized mTOR substrate is 4E-BP1, a translation regulator. With the 
recent phospho-proteomic studies that identified hundreds of direct and indirect targets of 
mTOR, we can begin to elucidate how the mTOR complexes could perform its wide array of 







Fig. 2. Overview of mTOR complex signaling and functions. Black arrows and gray lines 
represent activating and inhibitory connections, respectively. Dotted lines indicate possible 
links. 
6.1 Protein synthesis and maturation 
Protein synthesis, ie translation, utilizes huge amounts of energy and machinery (ie. 
ribosomes), and consequently, the entire process is under tight control (Acker & Lorsch 2008; 
Malys & McCarthy 2011). mTOR, primarily mTORC1, is involved in different aspects of 
protein synthesis (Ma & Blenis 2009; Sonenberg & Hinnebusch 2009). Its most well 
characterized function is the phosphorylation of proteins involved in translation initiation, 
namely S6K1 and 4E-BP. 4E-BP is a negative regulator of translation initiation (Pause et al. 
1994). When unphosphorylated, it interacts with eIF-4E (eukaryotic initiation factor 4E) cap-
binding protein, preventing cap-dependent translation. mTORC1-mediated phosphorylation 
dissociates 4E-BP1 from eIF-4F and releases the inhibition of translation (Ma & Blenis 2009; 
Sonenberg & Hinnebusch 2009). However, there are four phosphorylation sites on 4E-BP1 that 
are regulated by mTORC1 but only two of them are sensitive to acute rapamycin treatment 
(Gingras et al. 1999; Gingras et al. 2001; Wang et al. 2003). In the presence of growth signals, 
translation of proteins specifically involved in cell proliferation is upregulated in a 4E-BP-
dependent fashion (Dowling et al. 2010). This would suggest that mTORC1 can specifically 
regulate the translation of a subset of mRNA under a particular growth condition. 
mTORC1 can directly phosphorylate and activate S6K1, which promotes mRNA translation 
by modulating multiple substrates involved in different stages of translation, from mRNA 
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surveillance, initiation to translation elongation (Ma & Blenis 2009). Phosphorylated S6K1 
binds to newly spliced mRNAs through its binding partner, SKAR (S6K1 aly/REF-like 
target) and potentially facilitate translation initiation and/or elongation (Ma et al. 2008). 
This protein complex interacts with EJC (exon junction complex), which monitors the 
quality of newly spliced mRNA (Ma et al. 2008). Active S6K1 also phosphorylates the 40S 
ribosomal protein S6 (rpS6) at several sites. Phosphorylated rpS6 is widely used as a readout 
of mTORC1 activity. Its phosphorylation appears to play a role in the control of cell size but 
is dispensable for translation of mRNA with 5’ terminal oligopyrimidine tract (TOP 
mRNAs) (Ruvinsky et al. 2005). S6K also phosphorylates PDCD4 (programmed cell death 4), 
an inhibitor of RNA helicase eIF4A. PDCD4 levels become downregulated upon 
phosphorylation (Dorrello et al. 2006). The degradation of PDCD4 greatly enhances eIF4A 
helicase activity and facilitates 40S ribosomal subunit scanning to the initiation codon. 
Moreover, S6K can also augment eIF-4A activity through increasing the levels of eIF-4A, 
eIF-4B, and eIF3 complex. The S6K-mediated phosphorylation of eIF4B can enhance its 
binding to eIF3 (Vornlocher et al. 1999). Thus, S6K can modulate a number of proteins 
involved in translation initiation. It could also regulate the elongation phase of translation. 
Phosphorylation of eEF2K (eukaryotic elongation factor 2 kinase) by S6K inhibits its activity 
towards eEF2 and consequently enhances elongation (Wang et al. 2001).  
In addition to the regulation of the translation process, mTORC1 directly affects the 
biosynthesis of the translational machinery as well. The assembly of functional ribosomes is 
an energy-demanding process requiring a series of building components and assembly 
factors (Mayer & Grummt 2006). mTORC1 has been found to regulate ribosome biogenesis 
at different levels, including the production of ribosomal proteins (Cardenas et al. 1999; 
Hardwick et al. 1999), pre-rRNA processing (Powers & Walter 1999), and the rRNA 
synthesis (Hardwick et al. 1999; Hannan et al. 2003). In response to extracellular conditions, 
mTORC1 can coordinate all three nuclear RNA polymerases, Pol I, Pol II and Pol III, to 
control ribosome synthesis (Beck & Hall 1999; Miller et al. 2001; Yuan et al. 2002; Martin et 
al. 2004; White 2005). mTORC1 regulates the nuclear translocation of TIF1A, a transcription 
factor that is essential for Pol I-associated transcription initiation (Mayer et al. 2004). 
Furthermore, mTORC1 activity can enhance the tRNA levels via regulation of the 
transcription of Pol III (Shor et al. 2010). Maf1, a Pol III suppressor, directly associates with 
and inhibits Pol III apparatus (Reina et al. 2006). Under growth-favorable conditions, 
mTORC1 phosphorylates Maf1 to dissociate it from Pol III and promotes its cytoplasmic 
translocation (Shor et al. 2010). mTORC1 also interacts with rDNA (ribosomal DNA) 
promoters to promote Pol I and Pol III transcription in a growth factor-dependent and 
rapamycin-sensitive manner (Tsang et al. 2010). 
mTORC2 is also emerging to play a role in translation. A more pronounced defect in protein 
synthesis and polysome assembly occurs upon mTOR inhibition with active site inhibitors, in 
contrast to rapamycin treatment (Yu et al. 2009; Carayol et al. 2010; Oh et al. 2010; Evangelisti 
et al. 2011). Although it can be argued that the exacerbated defects could be due to inhibition 
of rapamycin-insensitive mTORC1 functions, there is some evidence that mTORC2 inhibition 
could contribute to these defects. First, polysome recovery is somewhat defective in mTORC2-
disrupted cells (Oh et al. 2010; Wu and Jacinto, unpublished results). Second, phosphorylation 
of eEF2 is aberrant in these cells. Most importantly, mTORC2 associates with actively 






et al. 2010; Zinzalla et al. 2011). mTORC2 components can stably associate with ribosomal 
proteins that are present at the tunnel exit. This would be consistent with the finding that 
mTORC2 can cotranslationally phosphorylate the emerging nascent Akt polypeptide (Oh et al. 
2010). Thus, mTORC2 could function in cotranslational maturation of newly synthesized 
proteins by phosphorylating relevant sites. The maturation of conventional PKC is also 
mediated by mTORC2 via phosphorylation (Facchinetti et al. 2008; Ikenoue et al. 2008).It 
would be interesting to see if mTORC2 could also cotranslationally phosphorylate PKC and 
whether it has additional cotranslational targets other than Akt. 
6.2 Autophagy  
Autophagy is a catabolic process that recycles intracellular components in the lysosomes to 
salvage substrates for energy production when nutrients become limiting (Noda, 1998; 
Janku, 2011). The control of this process by TOR was first discovered in yeast. In yeast, 
active TORC1 correlates with hyperphosphorylation of Atg13, a regulatory component of 
the Atg1 complex. Under this condition, assembly of the Atg1-Atg13 complex is inhibited 
thereby preventing autophagy (Yorimitsu et al. 2009; Kamada et al. 2010; Kijanska et al. 
2010; Yeh et al. 2010). Increased autophagy is observed upon rapamycin treatment, 
supporting the role of TORC1 in regulating this cellular process (Kamada et al. 2000).  
Under nutrient-replete conditions, mTOR negatively regulates autophagy by interacting 
with a protein complex composed of ULK1 (UNC51 like kinase), Atg13, and FIP200 (Ganley 
et al. 2009; Hosokawa et al. 2009; Jung et al. 2009). This complex is involved in the formation 
of the autophagosomes. The phosphorylation of ULK1 and Atg13 is inhibited by rapamycin 
treatment and leucine deprivation, implying the link between mTORC1 and autophagy 
(Hosokawa et al. 2009; Jung et al. 2009).  
mTOR is also involved in regulating expression of genes that are involved in 
autophagosome or lysosome biogenesis. mTORC1 could mediate phosphorylation of the 
transcription factor EB (TFEB), thereby controlling its nuclear shuttling and activity. TFEB 
binds E box related DNA sequences and controls lysosomal gene transcription (Pena-Llopis 
et al. 2011; Settembre et al. 2011). mTORC2 could also be involved in the control of 
autophagy via Akt-FoxO signaling (Mammucari et al. 2007). Disruption of rictor enhanced 
autophagosome formation in skeletal muscle and that this effect was abrogated upon 
expression of constitutively active Akt in the absence or presence of rapamycin, indicating 
that in this cell type, autophagy is dependent on mTORC2 function, not mTORC1 
(Mammucari et al. 2007). Indeed, attenuated Akt activity caused by downregulation of 
mTORC2 leads to decreased phosphorylation and increased nuclear translocation of FoxO3 
(Shiojima & Walsh 2006). FoxO3 induces the expression of many autophagy-related genes, 
such as Atg12l and Ulk2, and increases autophagosome formation in isolated adult mouse 
muscle fibers (Zhao et al. 2007). Together, these results indicate that by directly interacting 
with autophagic proteins or modulating the transcription of autophagy-related genes, 
mTOR complexes regulate autophagy. 
6.3 Metabolism 
Early studies showing reduced fungal amino acid, nucleic acid, and lipid metabolism after 
rapamycin treatment have linked TOR to metabolic functions (Singh et al. 1979). Later 
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transcription profiling screening of lymphoma cells treated with rapamycin revealed a 
tendency towards catabolism and that the levels of many mRNA involved in lipid, 
nucleotide, and protein synthesis were downregulated (Peng et al. 2002). In the whole 
organism, the function of mTOR in metabolism is underscored by findings on the effect of 
rapamycin treatment on insulin-responsive tissues. Inhibition of mTORC1 in mice via 
feeding with rapamycin induced diabetes due to smaller pancreatic islets and abolished 
insulin secretion (Bussiere et al. 2006). This effect could be mediated via S6K and S6 since 
these two mTORC1 pathway effectors are also required for the normal morphology and 
function of pancreatic islet cells and that removal of these two proteins led to a diabetic 
phenotype (Ruvinsky et al. 2005). Corollary to this, hyperactivation of mTORC1 occuring 
in TSC knockout resulted in larger islet size and higher number of -cell (Rachdi et al. 
2008). Together, these findings support a role for mTORC1 in maintaining metabolic 
homeostasis.  
Recent studies, discussed below, that have employed mTORC component gene ablation or 
knockdown further demonstrate the central role of mTOR in cellular and systemic 
metabolism. The critical role of mTORC1 in cellular metabolism is illustrated by its 
involvement in the biogenesis of mitochondria. In muscle-specific raptor knockout mice, 
there are reduced levels of PGC1 (PPAR coactivator 1), which is required for 
mitochondrial gene expression (Cunningham et al. 2007). In these mice, the skeletal muscle 
has lower mitochondria number, reduced oxidative capacity, and elevated glycogen storage, 
which led to muscle dystrophy (Bentzinger et al. 2008). Moreover, by genomic analysis, YY1 
(yin-yang 1), a transcription factor that regulates mitochondrial gene expression and oxygen 
consumption, was identified as a downstream effector of mTORC1 (Cunningham et al. 
2007). Both mTOR and raptor can bind to YY1 while rapamycin treatment inhibited YY1 
activity by preventing its interaction with the coactivator, PGC1 (Cunningham et al. 2007). 
Rapamycin treatment of or knockdown of mTOR or raptor in muscle cells also reduced 
mitochondrial gene transcription and respiratory metabolism (Cunningham et al. 2007). 
Interestingly, this function of mTORC1 appears to be S6K1-independent. In line with these 
findings, enhanced muscular levels of PGC1 and mitochondria were found in S6K1 
knockout mice (Um et al. 2004). Thus, mTORC1, via YY1 and PGC1, could regulate 
mitochondrial gene expression and thereby enhance mitochondrial oxidative functions.  
In addition to skeletal muscle, raptor knockout in other insulin-responsive tissues further 
illustrate the role of mTORC1 in metabolism. In adipose-specific raptor knockout mice, 
adipose tissue was reduced and these mice were protected against diet-induced obesity and 
hypercholesterolemia. There was elevated expression of genes involved in mitochondrial 
respiration in white adipose tissue and the leanness of these mice could be explained by 
enhanced energy expenditure due to mitochondrial uncoupling (Polak et al. 2008).  These 
mice also display higher glucose tolerance and insulin sensitivity. This could be due to 
defective S6K feedback regulation of IRS-1 activity, causing hyperactivated insulin receptor 
signaling (Polak et al. 2008). These findings underscore the role of adipose mTORC1 in 
whole body energy homeostasis. 
In liver, inhibition of mTORC1 promotes hepatic ketogenesis in response to fasting (Sengupta 
et al. 2010). Active mTORC1 negatively regulates PPAR (peroxisome proliferator activated 
receptor ), the master transcriptional activator of ketogenic gene expression, through 






Thus, mice with hyperactivation of mTORC1 upon loss of TSC1 in the liver manifest defects 
in ketone body production and enlarged liver size during fasting (Sengupta et al. 2010).  
Other effectors of mTORC1 in the control of metabolic processes have emerged in recent 
reports. mTORC1 can modulate sterol and lipid biosynthesis through SREBP-1 (sterol 
regulatory element binding protein-1), a transcription factor that controls lipo- and 
sterolgenic gene transcription (Porstmann et al. 2008; Duvel et al. 2010). The mTORC1 target 
S6K1 can partially promote the activity of SREBP-1 via posttranslational modification. More 
recently, one critical regulator of mTORC1-SREBP-1 pathway has been identified. Lipin 1, 
which is directly phosphorylated and sequestered in the cytoplasm by mTORC1, induces 
the translocation of SREBP-1 into cytoplasm and negatively regulates its activity as a 
transcription factor (Peterson et al. 2011). Under high-fat and –cholesterol diet, mTORC1 
activity is required for SREBP-1 function to promote fat accumulation and 
hypercholesterolemia in mice (Peterson et al. 2011). mTORC1 can also modulate the 
expression level of Hif1 (hypoxia-inducible factor ), which activates numerous hypoxia-
induced genes involved in cellular metabolic processes including those involved in 
glycolysis and glucose uptake (Goldberg et al. 1988; Brugarolas et al. 2003; Duvel et al. 2010).  
There is also accumulating evidence that mTORC2 is required in metabolic processes. 
Knockdown of rictor in MEFs diminished metabolic activity (Shiota et al. 2006). 
Furthermore, deficiency of rictor in Jurkat cells, a leukemic T cell line, increased oxygen 
consumption (Schieke et al. 2006). However, mTORC2 could play a more complex function 
in mitochondrial metabolism since a PTEN-deficient cell line that is mTORC2 addicted/IL3-
independent was shown to require a number of genes involved in mitochondrial functions 
(Colombi et al. 2011). Adipose-specific knockout of rictor in mice revealed that mTORC2 can 
function to control whole body growth (Cybulski et al. 2009). In these mice, there was 
increased size of non-adipose organs, such as heart, kidney, spleen, and pancreas (Cybulski 
et al. 2009). In addition, these mice also displayed hyperinsulinemia and elevated levels of 
IGF (insuline-like growth factor) and IGFBP3 (IGF binding protein 3) (Cybulski et al. 2009). 
Conversely, the deletion of rictor in pancreatic -cells decreased their proliferation and 
mass, which led to reduced insulin secretion, hyperglycemia, and glucose intolerance in 
mice (Gu et al. 2011). Specific effectors of mTORC2 function in metabolism remain to be 
characterized. Future investigation should reveal how mTORC1 and mTORC2 signaling 
pathways impinge on metabolic pathways. This would be important in light of 
understanding how defects in cellular metabolism that occurs in cancer and other 
pathological conditions are linked to aberrant mTOR signaling. 
6.4 Actin cytoskeleton reorganization  
The regulation of actin cytoskeleton reorganization is a conserved function of mTORC2. In 
S. cerevisiae, tor2 mutations or depletion of TORC2 components depolarizes the actin 
cytoskeleton (Schmidt et al. 1996; Loewith et al. 2002). Normal polarization of actin towards 
the growing bud controls spatial growth in yeast. In mammals, mTORC2 can control actin 
polymerization and cell spreading via Rho and Rac, members of the Rho family of GTPases 
that regulates F-actin assembly (Jacinto et al. 2004). Rex1, a Rac GEF, links mTOR signaling 
to Rac activation and regulates cell migration (Hernandez-Negrete et al. 2007). PKC, which 
is phosphorylated by mTORC2, is also linked to actin cytoskeleton reorganization in 
mammalian cells (Sarbassov et al. 2004). However, it remains unclear how the mTORC2-
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dependent phosphorylation of PKC can promote the actin reorganization function of this 
AGC kinase.  
Studies using rapamycin have also linked actin cytoskeleton reorganization to the mTORC1 
pathway. Rapamycin inhibits the reorganization of F-actin and the phosphorylation of focal 
adhesion proteins through S6K1 (Berven et al. 2004; Liu et al. 2008). S6K1 is localized to actin 
stress fibers in fibroblasts (Crouch 1997) and S6K1, Akt, PDK1, and PI3K colocalized with 
the actin arc, a caveolin-enriched cytoskeletal structure located at the leading edge of 
migrating Swiss 3T3 cells (Berven et al. 2004). The mTORC1 pathway is also linked to cell 
motility and migration. Rapamycin inhibits cell motility in several cell types, such as 
neutrophils (Gomez-Cambronero 2003), vascular smooth muscle cells (Poon et al. 1996), and 
T-lymphocytes (Finlay & Cantrell 2010). The mTORC1 target, S6K, mediates cell migration 
via its regulation of focal adhesion formation (Liu et al. 2008), reorganization of F-actin 
(Berven et al. 2004; Liu et al. 2008), as well as the upregulation of the matrix 
metalloproteinase 9 (MM9) (Zhou & Wong 2006), and the activity and expression of RhoA 
(Liu et al. 2010). How mTORC1 or mTORC2 can more directly regulate its effectors in actin 
cytoskeleton reorganization remains to be examined. Future studies on how the mTORC-
mediated function in actin cytoskeleton reorganization is coupled to the other growth-
regulatory functions of mTORCs would need to be addressed. 
7. mTOR inhibitors and therapeutic significance 
Due to the central role of mTOR in cell survival, growth and proliferation, deregulation of 
the mTOR signaling pathway is implicated in many human diseases including benign and 
malignant tumors, neurological and metabolic disorders and cardiovascular diseases (Pei & 
Hugon 2008; Krymskaya & Goncharova 2009; Hwang & Kim 2011; Ibraghimov-Beskrovnaya 
& Natoli 2011). Moreover, its role in organismal aging is highlighted by findings that 
inhibition of the TOR/mTOR pathway can prolong lifespan in several organisms (Vellai et 
al. 2003; Kapahi et al. 2004; Medvedik et al. 2007; Harrison et al. 2009). Drawing lessons from 
rapamycin, numerous mTOR inhibitors have been developed and are currently being 
refined to achieve more specific inhibition. We discuss some recent findings on the use of 
these inhibitors at the bench and in the clinic.  
Rapamycin and its analogs (rapalogs) are allosteric mTOR inhibitors and form a complex 
with FKBP12 and mTOR. By binding at the FRB domain of mTOR, the interaction between 
mTOR and raptor is diminished and can uncouple mTOR from its substrates (Oshiro et al. 
2004). Rapamycin and derivatives such as CCI-779 (temsirolimus, Torisel), RAD001 
(everolimus), and AP23573 (ridaforolimus) act as cytostatic agents that slow down or arrest 
the growth of cells derived from several cancer types such as rhabdomyosarcoma (Hosoi et 
al. 1999), prostate cancer (van der Poel et al. 2003), breast cancer (Pang & Faber 2001), and B-
cell lymphoma (Muthukkumar et al. 1995). Early results from clinical trials reveal that they 
have antiproliferative activity in a subset of cancer, such as endometrial cancer (Oza et al. 
2011), pancreatic neuroendocrine tumors (Goldstein & Meyer 2011), gastric cancer (Doi et al. 
2010), and malignant glioma (Reardon et al. 2011). However, only a subset of mTORC1 
functions is sensitive to rapamycin treatment, hence the antiproliferative properties of this 
drug can be limited (Wang et al. 2005; Choo et al. 2008; Choo & Blenis 2009). In a number of 
cell types, the inhibition of mTORC1 results in the upregulation of the PI3K/Akt pathway. 






receptor substrate-1 (IRS-1) by phosphorylation at serine residues (Zhande et al. 2002; Shah 
& Hunter 2006; Tzatsos & Kandror 2006). The inhibition of mTORC1 by rapalogs disrupts 
this feedback loop and results in increased IRS1 signaling and Akt activity that may 
compromise the anti-tumor activity of mTOR inhibitors (Harrington et al. 2004; Shah et al. 
2004; Sun et al. 2005; O'Reilly et al. 2006). Since mTORC2 is a positive regulator of Akt, 
several new mTOR inhibitors that can block both mTORC1 and mTORC2 have been 
developed to more effectively inhibit mTOR signaling and cell proliferation. 
The pyrazolopyrimidine analogs PP242 and PP30 are ATP-competitive inhibitors of mTOR 
that bind to its ATP-binding site and as a result, block the kinase activities of both mTORC1 
and mTORC2 (Feldman et al. 2009). PP242 and PP30 both inhibit the mTORC2-induced 
phosphorylation of Akt at Ser473, indicating that these inhibitors can indeed interfere with 
mTORC2 functions. Furthermore, these two mTOR kinase domain inhibitors attenuate 
protein synthesis and proliferation of mouse embryonic fibroblasts (MEFs) (Feldman et al. 
2009). PP242 has been shown to induce cytoreduction and apoptosis in multiple myeloma 
cells (Hoang et al. 2010) and cause death of mouse and human leukemia cells and delay 
leukemia onset in vivo (Janes et al. 2010), highlighting the potential therapeutic application 
of this compound. Another ATP-competitive mTOR inhibitor, Torin1, induces cell cycle 
arrest and inhibits cell growth and proliferation more efficiently than rapamycin (Thoreen et 
al. 2009). Preclinical studies substantiate the therapeutic value of Torin1. For example, 
Torin1 treatment prevented the anti-inflammatory potency of glucocorticoids both in human 
monocytes and myeloid dendritic cells (Weichhart et al. 2011). Moreover, Torin1 
significantly inhibited the translation of viral proteins during human cytomegalovirus 
infection (Clippinger et al. 2011). Recently, Torin2, a novel mTOR inhibitor with improved 
pharmacokinetic properties and synthetic route, has been described (Liu et al. 2011). Torin2 
inhibits mTOR complexes with IC50 of 0.25 nM, compared to Torin1 at IC50 of 2 to 10 nM. 
Therefore, Torin2 is suggested to be a more potent and stable mTORC inhibitor than Torin1.  
Since mTORC1 inhibition leads to upregulation of IRS1 and subsequently PI3K, which in 
turn activates Akt, simultaneously blocking the activities of mTOR complexes and PI3K may 
inhibit cell proliferation and growth more effectively. As a result, several mTOR/PI3K dual 
inhibitors have been developed. NVP-BEZ235 inhibits PI3K and mTOR kinase activity by 
interacting with their ATP-binding domains (Maira et al. 2008). It has been implicated in the 
treatment of non-small cell lung cancer (Konstantinidou et al. 2009), melanoma (Marone et 
al. 2009), pancreatic cancer (Cao et al. 2009), and acute myeloid leukemia (Chapuis et al. 
2010). Given the compensatory mechanisms that cells employ to adapt to growth-inhibitory 
conditions, it would be important to identify signaling pathways that impinge on the 
mTOR/PI3K pathway in order to develop combinatorial therapy for preventing 
malignancy. 
8. Conclusion 
Two decades after the discovery of TOR/mTOR, the function of this protein in orchestrating 
cellular processes in response to growth signals particularly nutrients has been established. 
Some key discoveries in the last few years that allowed more extensive analysis of mTOR 
function and regulation include identification of the mTOR complexes and regulatory 
proteins that link the mTOR pathway to nutrient and energy responses and the 
development of mTOR inhibitors. Studies to dissect the systemic function of mTOR 
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complexes are also gaining momentum with the use of tissue-specific mTORC component 
knockout mice. There are still numerous outstanding questions that need to be addressed 
such as the precise regulation of mTOR complexes by nutrients, how it links signals from 
nutrients to cellular metabolism and other processes, and distinct functions and regulation 
of mTORCs in different cellular compartments. The recent identification of the myriad 
possible direct and indirect targets of the mTORCs should provide clues on the mechanisms 
involved in mTOR functions. Animal models would also provide insights on the role of 
mTOR in physiological and pathological conditions. Finally, development of specific 
mTORC1 and mTORC2 inhibitors would not only be useful to determine the distinct 
functions of these complexes but also would have numerous clinical applications. 
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